Abstracts tagged "SLE"

Abstract Number: 2089 • 2018 ACR/ARHP Annual Meeting
The Differential Impact of the Abrogation of the Costimulatory Molecule CD137 Ligand on Renal and Cerebral Manifestations in C57BL/6.Faslpr-/- mice
Anselm Mak¹, Bhushan Dharmadhikari², Lik Wei Wong², Saji Kumar Sreedharan² and Herbert Schwarz², ¹Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Background/Purpose: Costimulatory molecules which mediate cross-talks between leukocytes, have been identified to play a pathogenetic pivotal role in systemic lupus erythematosus (SLE). Abrogation of the…
Abstract Number: 2356 • 2018 ACR/ARHP Annual Meeting
Perceptions, Incentives, and Barriers to Clinical Trial Participation: Qualitative Evaluation of Lupus Patients, Enriched for Minority Participants
Cristina Arriens¹, Fredonna Carthen², D'Angelo Grant², Paul Kamp¹, Stan Kamp¹, Katherine Thanou¹, Teresa Aberle¹, Eliza Chakravarty¹, Judith A. James³, Joan T. Merrill¹ and Motolani E. Ogunsanya⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, OKLAHOMA CITY, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Although SLE disproportionately affects minority racial groups, they are significantly under-represented in clinical trials. This may lead to false, underpowered conclusions in race-based sub-group…
Abstract Number: 102 • 2018 ACR/ARHP Annual Meeting
Estrogen Controls the Expression of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in Human T Lymphocytes Via Transcriptional and Post-Transcriptional Mechanisms
Julian F. Oviedo¹, Elena N. Cravens¹ and Vaishali R. Moulton^2,3, ¹Beth Israel Deaconess Medical Center, Harvard Medical School, Medicine/Rheumatology, Boston, MA, ²Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ³Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic debilitating autoimmune disease that primarily afflicts women in the childbearing years. Female hormones especially estrogen are implicated…
Abstract Number: 758 • 2018 ACR/ARHP Annual Meeting
Cutaneous Lupus Erythematosus Patients with a Negative ANA Meeting Acr and/or SLICC Criteria for Systemic Lupus Erythematosus
Meera Tarazi¹, Carolyn Kushner², Rebecca Gaffney² and Victoria P. Werth³, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ²Dermatology, University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a disorder that is heterogeneous and can be difficult to diagnose. One hallmark of the disease is the presence…
Abstract Number: 1099 • 2018 ACR/ARHP Annual Meeting
Ongoing DNA Damage, Chromatin Deregulation and Defective DNA Damage Response in Systemic Autoimmune Rheumatic Diseases
Maria Pappa¹, Nikolaos I. Vlachogiannis¹, Alexandra Argyriou¹, Vassilis L. Souliotis² and Petros Sfikakis³, ¹National Kapodistrian University of Athens Medical School, Athens, Greece, First Department of Propaedeutic and Internal Medicine & Rheumatology Unit, National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ²National Hellenic Research Foundation, Athens, Greece, Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece, Athens, Greece, ³Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Athens University Medical School, Athens, Greece
Background/Purpose: Recent data highlight that patients with Systemic Lupus Erythematosus (SLE) have defects in two main DNA repair pathways, namely nucleotide excision repair (NER) and…
Abstract Number: 2091 • 2018 ACR/ARHP Annual Meeting
Mucosal-Associated Invariant T (MAIT) Cells As a Potential Therapeutic Target for Systemic Lupus Erythematosus
Goh Murayama¹, Asako Chiba², Atsushi Nomura³, Hirofumi Amano¹, Ken Yamaji¹, Naoto Tamura¹ and Sachiko Miyake^4,5, ¹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Juntendo Univ Sch of Med, Juntendo University School of Medicine, Tokyo, Japan, ³JUNTENDO UNIVERSITY SCHOOL OF MEDICINE, Tokyo, Japan, ⁴Division of Immunology/NCNP, Natl Institute of Neuroscience, Kodaira Tokyo, Japan, ⁵Immunology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain:…
Abstract Number: 2436 • 2018 ACR/ARHP Annual Meeting
The Impact of Different Classes of Lupus Nephritis on Maternal and Fetal Outcomes
Bruna Costa Rodrigues¹, Marcela Ignacchiti Lacerda¹, Guilherme Ramires de Jesus², Flavia Cunha dos Santos², Nilson Ramires de Jesus², Roger Abramino Levy^1,3 and Evandro Mendes Klumb¹, ¹Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Immunology and Inflammation, GlaxoSmithKline, Upper Providence, PA
Background/Purpose: During pregnancy, history of lupus nephritis (LN) has been independently associated with increased risk of adverse maternal and fetal outcomes, which are even more…
Abstract Number: 104 • 2018 ACR/ARHP Annual Meeting
Identification of a Gut Pathobiont Immunostimulatory Lipoglycan Antigen Linked to Lupus Nephritis
Gregg Silverman¹, Nicolas Gisch², Aidana Omarbekova³ and Doua F. Azzouz⁴, ¹Department of Medicine, New York University School of Medicine, New York, NY, ²Research Center Borstel, Schleswig-Holstein, Germany, ³New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY
Background/Purpose: A transmissible agent has long been suspected in SLE. In a discovery cohort we found that,compared with healthy subjects, Lupus patients had a five-fold…
Abstract Number: 759 • 2018 ACR/ARHP Annual Meeting
Comparison of Length of Stay and Total Hospital Charges for Hospitalizations for Sepsis in Patients with Systemic Lupus Erythematosus: A Study of National Inpatient Sample Database 2010 to 2014
Karan Chugh¹, Shraddha Jatwani², Karan Jatwani³ and Jasleen Kaur⁴, ¹Division of Pulmonary, Critical Care & Sleep, Wayne State University/Detroit Medical Center, Detroit, MI, ²Department of Internal Medicine, Division of Rheumatology, Henry Ford Allegiance Health, Jackson, MI, ³Department of Internal Medicine, Mount Sinai West - St Luke’s Hospital, New York, NY, ⁴Department of Internal Medicine, Wayne State University/Detroit Medical Center, Detroit, MI
Background/Purpose: Sepsis is a systemic inflammatory response syndrome caused by an infection with at least one acute organ failure and is major public health concern.1…
Abstract Number: 1388 • 2018 ACR/ARHP Annual Meeting
Characteristics and Symptom Severity in 21,101 Patients Reporting Systemic Lupus Erythematous in the Patientslikeme Online Health Community
Elisabeth Nyman¹, Edward R. Hammond², Timothy Vaughan³, Barnabas Desta², Xia Wang², Volkan Barut⁴ and Cathy Emmas⁵, ¹Advanced Analytics Centre, AstraZeneca, Gothenburg, Sweden, ²AstraZeneca, Gaithersburg, MD, ³PatientsLikeMe, Boston, MA, ⁴Global Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ⁵Patient Centricity, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: Online health communities and research networks such as PatientsLikeMe (PLM) provide important insight into understanding chronic diseases, including systemic lupus erythematous (SLE). We aimed…
Abstract Number: 2092 • 2018 ACR/ARHP Annual Meeting
Glucocorticoid-Induced Leucine Zipper (GILZ) Is a Novel Checkpoint Regulator of Type I Interferon (IFN) Production in SLE
Champa Nataraja¹, Eric Morand¹, Jacinta Lee¹, Taylah Bennett¹, Jacqueline Flynn¹, James Harris¹ and Sarah Jones², ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Glucocorticoids (GC) remain the frontline treatment in Systemic Lupus Erythematosus (SLE) despite their predictable metabolic adverse effects. Type I interferons (IFN), produced by TLR7…
Abstract Number: 2441 • 2018 ACR/ARHP Annual Meeting
Needs and Barriers to Pregnancy Counselling in Women with SLE
Autumn Neville¹, Natalie Dayan¹, Cheryl Barnabe², Susan Elliott³, Laurie Proulx⁴, Deborah Da Costa⁵, Sasha Bernatsky⁶ and Evelyne Vinet⁷, ¹McGill University Health Centre, Montreal, QC, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³GEOGRAPHY AND ENVIRONMENTAL MANAGEMENT, University of Waterloo, Waterloo, ON, Canada, ⁴Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, ⁵Medicine, McGill University, Montreal, QC, Canada, ⁶Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁷Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Existing data suggest that barriers to pregnancy counselling exist and might represent an area of need in order to optimize outcomes for SLE pregnancies.…
Abstract Number: 107 • 2018 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants, Renal Histopathology, and Prognosis in African American SLE Nephritis Patients: A Cohort Study
Ashira Blazer¹, Ming Wu², Nancyanne Schmidt³, Alana Engelbrecht⁴, Feng-Xia Liang⁵, Robert M. Clancy⁶, Jill P. Buyon⁷ and H. Michael Belmont⁸, ¹Internal Medicine Division of Rheumatology, NYU School of Medicine, New York, NY, ²Department of Pathology, New York University, New York, NY, ³Internal Medicine, New York University School of Medicine, New York, NY, ⁴Rheumatology, NYU Langone Health, New York, NY, ⁵Office of Science and Research, New York University School of Medicine, New York, NY, ⁶Colton Center for Autoimmunity, New York University, New York, NY, ⁷Rheumatology, NYU School of Medicine, New York, NY, ⁸Division of Rheumatology, New York University, New York, NY
Background/Purpose: Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2, associate with CKD in African Americans (AA) and are evolutionarily preserved due to improved infectious…
Abstract Number: 773 • 2018 ACR/ARHP Annual Meeting
Exploring the Relation between Immunoglobulins Level and Infection Risk in Adult Patients with Systemic Lupus Erythematosus
Ibrahim Almaghlouth^1,2, Jiandong Su³, Eleanor Pullenayegum⁴, Sindhu Johnson⁵, Dafna D Gladman³ and Murray Urowitz⁶, ¹Division of Rheumatology, Department of medicine, King Saud University, King Khalid University Hospital, Riyadh, Saudi Arabia, ²Division of Rheumatology, Department of medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, ⁵Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ⁶Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Infection is a major cause of mortality in all stages of disease in systemic lupus erythematosus (SLE). Several risk factors for infection have been…
Abstract Number: 1389 • 2018 ACR/ARHP Annual Meeting
Depression and the Patient Reported Outcomes Measurement Information System in Systemic Lupus Erythematosus
Brett Dietz¹, Patricia Katz¹, Maria Dall'Era², Louise Murphy³, Cristina Lanata¹, Laura Trupin¹ and Jinoos Yazdany², ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Health-related quality of life (HRQoL) is reduced in SLE. Depression is a possible contributor to reduced HRQoL. The relationship between major depression and HRQoL…

« Previous Page
1
…
6
7
8
9
10
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].